Nature3 个月
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by ...
Nature9 年
Fas counter-attack–the best form of tumor defense?
New in vivo evidence confirms that tumor-expressed Fas ligand impairs immune responses to cancer by inducing apoptosis of anti-tumor immune effector cells. A recent report demonstrated that murine ...
Therapeutic approach to treat virus-induced lung failure for severe COVID-19 shows promise ...
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
News Medical on MSN12 天
FasL inhibitor speeds recovery and reduces mortality in severe COVID-19 patients
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
EurekAlert!14 天
New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight days ...
Medindia12 天
Faster Recovery, Fewer Deaths: The Latest COVID-19 Therapeutic Innovation
The latest COVID-19 treatment, using an inhibitor of the Fas ligand (FasL), also known as CD95 ligand (CD95L), speeds up ...